Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (1824)	9/15/2003 8:20:44 PM
From: SemiBull	Read Replies (1) \| Respond to of 3044

Medicines Co Hopes Trial Accelerates Angiomax Use "... However, Dr. C. Michael Gibson, of Brigham & Woman's Hospital in Boston, who is working with Millennium Pharmaceuticals Inc. (NasdaqNM:MLNM - News) on another trial comparing Angiomax to heparin plus GPIIb/IIIa, said he had some concerns about Replace-2. The dosage of heparin in the trial, he said, was higher than what's actually being used now by most physicians, which may have meant more bleeding in this set of patients. 'Excessive heparin doses may have led to excessive bleeding and myocardial infarctions,' Gibson said in an interview. The average doctor, he added, isn't giving heparin at these levels. 'The trend is to go down (on dosage), not up.' Millennium makes Integrilin, one of the leading GPIIb/IIIa's ..." biz.yahoo.com